Skip to content
Clinical Trials – home

Find therapies in clinical trials near you

recruiting
3 968
countries
28
conditions
2 103

26 trials match your criteria

Breast cancer+2

Recruiting

A Study Comparing RLY-2608 and Fulvestrant with Capivasertib and Fulvestrant for Patients with PIK3CA-Mutant Hormone Receptor Positive, HER2-Negative Advanced Breast Cancer

Registered drugNo placebo
Countries:LuxembourgLuxembourg
  • Participants:18–64 years · 65+ years
  • Substances:Capivasertib

Prostate cancer

Recruiting

A study of saruparib with radiotherapy and hormone therapy for men with high-risk prostate cancer who have a BRCA gene mutation

Registered drug
Countries:LuxembourgLuxembourg
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone Acetate

Study Comparing Single and Dual Antiplatelet Therapy with Clopidogrel and Acetylsalicylic Acid in Elderly Patients or Those at Risk of Bleeding After Balloon Surgery

Registered drugNo placebo
Countries:LuxembourgLuxembourg
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
Countries:LuxembourgLuxembourg
  • Participants:18–64 years · 65+ years
  • Substances:Autologous Adipose-Derived Stem Cells

Radius fracture

Recruiting

Study on Long-term Safety of NVDX3 Implant for Patients with Distal Radius Fracture or Low-grade Degenerative Lumbar Spondylolisthesis

InvestigationalNo placebo
Countries:LuxembourgLuxembourg
  • Participants:18–64 years
  • Substances:Nvdx3

Study Comparing Short-Course Radiotherapy and Drug Combination for Older Patients with Locally Advanced Rectal Cancer

Registered drugNo placebo
Countries:LuxembourgLuxembourg
  • Participants:65+ years
  • Substances:Capecitabine

Embolism

Not yet recruiting

A study to evaluate the effectiveness of REGN7508 for preventing blood clots in adults with solid tumors undergoing cancer treatment.

Investigational
Countries:LuxembourgLuxembourg
  • Participants:18–64 years · 65+ years
  • Substances:Regn7508

Parkinson's disease

Not yet recruiting

Efficacy of intravenous prasinezumab versus placebo in Parkinson's disease patients with severe GBA mutation: a 104‑week randomized double‑blind study

Registered drug
Countries:LuxembourgLuxembourg
  • Participants:18–64 years · 65+ years
  • Substances:Prasinezumab

Study on the Effectiveness of Paclitaxel, Carboplatin, and Durvalumab for Patients with Extensive Stage Small Cell Lung Cancer

Registered drugNo placebo
Countries:LuxembourgLuxembourg
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin

Study of Lorigerlimab and Docetaxel for Patients with Metastatic Castration-Resistant Prostate Cancer

Registered drugNo placebo
Countries:LuxembourgLuxembourg
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone

Study of Vobramitamab Duocarmazine and Prednisone for Patients with Metastatic Castration-Resistant Prostate Cancer

Registered drugNo placebo
Countries:LuxembourgLuxembourg
  • Participants:18–64 years · 65+ years
  • Substances:Prednisone

Study on Trilaciclib and Topotecan for Patients with Extensive Stage Small Cell Lung Cancer

Registered drug
Countries:LuxembourgLuxembourg
  • Participants:18–64 years · 65+ years
  • Substances:Glucose Monohydrate
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.